SP1 and cancer: The −765 G > C (rs20417) located at the transcription start site prevents Sp1 binding but creates a new E2 promoter factor (E2F) binding site, leading to high transcription activity, which may be the mechanism underlying the increased cancer risk associated with −765 G > C (rs20417) polymorphism [30].